HighTower Advisors LLC Acquires 10,921 Shares of Fractyl Health, Inc. (NASDAQ:GUTS)

HighTower Advisors LLC grew its holdings in Fractyl Health, Inc. (NASDAQ:GUTS) by 72.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 25,921 shares of the company’s stock after purchasing an additional 10,921 shares during the quarter. HighTower Advisors LLC owned approximately 0.05% of Fractyl Health worth $53,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of GUTS. Raymond James Financial Inc. bought a new position in Fractyl Health in the fourth quarter worth approximately $34,000. Conservest Capital Advisors Inc. bought a new position in shares of Fractyl Health in the 4th quarter worth $132,000. Parkside Financial Bank & Trust purchased a new stake in shares of Fractyl Health during the 4th quarter worth $27,000. Bank of New York Mellon Corp boosted its position in Fractyl Health by 27.3% during the fourth quarter. Bank of New York Mellon Corp now owns 41,448 shares of the company’s stock valued at $85,000 after purchasing an additional 8,886 shares in the last quarter. Finally, Rhumbline Advisers grew its stake in Fractyl Health by 73.1% in the fourth quarter. Rhumbline Advisers now owns 25,626 shares of the company’s stock valued at $53,000 after purchasing an additional 10,826 shares during the last quarter.

Insiders Place Their Bets

In other Fractyl Health news, insider Jay David Caplan sold 22,346 shares of Fractyl Health stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $1.81, for a total transaction of $40,446.26. Following the completion of the sale, the insider now owns 153,544 shares of the company’s stock, valued at approximately $277,914.64. The trade was a 12.70 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Harith Rajagopalan sold 90,972 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $1.82, for a total value of $165,569.04. Following the sale, the chief executive officer now owns 491,329 shares in the company, valued at approximately $894,218.78. The trade was a 15.62 % decrease in their position. The disclosure for this sale can be found here.

Fractyl Health Stock Performance

Shares of GUTS opened at $1.12 on Friday. The company has a current ratio of 5.58, a quick ratio of 5.57 and a debt-to-equity ratio of 0.60. The firm has a market cap of $54.79 million, a PE ratio of -0.09 and a beta of 0.30. Fractyl Health, Inc. has a 12 month low of $1.07 and a 12 month high of $7.89. The stock has a fifty day moving average price of $1.45 and a 200-day moving average price of $1.99.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.08). Equities research analysts predict that Fractyl Health, Inc. will post -1.61 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Morgan Stanley lowered their price target on shares of Fractyl Health from $18.00 to $10.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd.

Fractyl Health Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.